{
    "clinical_study": {
        "@rank": "90756", 
        "arm_group": [
            {
                "arm_group_label": "Fixed dose combination", 
                "arm_group_type": "Experimental", 
                "description": "Linagliptin/Metformin"
            }, 
            {
                "arm_group_label": "Free combination", 
                "arm_group_type": "Experimental", 
                "description": "Linagliptin and Metformin"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the current study is to demonstrate bioequivalence of two 2.5 mg\n      linagliptin/500 mg metformin fixed dose combination tablets compared to the free combination\n      of the linagliptin 5 mg and metformin 1000 mg in healthy male and female volunteers."
        }, 
        "brief_title": "Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto\u00ae.", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Signed and dated written informed consent prior to admission to the study in\n             accordance with Good Clinical Practice and the local legislation\n\n          -  Healthy males and females according to the following criteria:\n\n        Based upon a complete medical history, including physical examination, vital signs (BP,\n        PR), 12-lead ECG and clinical laboratory tests (haematology, clinical chemistry and\n        urinalysis).\n\n          -  Age 18 to 45 years (incl.)\n\n          -  Body mass index by Quetelet between 18.50 to 24.99 kg/m2 (incl.)\n\n          -  Female subjects of childbearing potential who agree on using double-barrier\n             contraception during the study. If a female is postmenopausal (no menses for at least\n             2 years) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or\n             hysterectomy) she will be exempt from the requirement. In case of using oral\n             contraceptives, these should be withdrawn at least 2 months before the first drug\n             dosing.\n\n          -  Male subjects who agree on using effective contraception during the study (barrier\n             contraceptive methods)\n\n        Exclusion criteria:\n\n          -  Any finding of the medical examination (including BP, PR and ECG) deviating from\n             normal and of clinical relevance\n\n          -  Any laboratory value outside the reference range that is of clinical relevance\n\n          -  Any evidence of a clinically relevant concomitant disease\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          -  Positive results of blood tests for infections (HIV, syphilis, hepatitis B or C)\n\n          -  A positive urine drug screening test at screening and on admission to the trial site\n             in each treatment period.\n\n          -  A positive alcohol breath test at screening and on admission to the trial site in\n             each treatment period.\n\n          -  Surgery of the gastrointestinal tract (except appendectomy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947153", 
            "org_study_id": "1288.21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Free combination", 
                "description": "Free combination", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fixed dose combination", 
                "description": "Fixed dose combination", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fixed dose combination", 
                "description": "Combination", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Free combination", 
                "description": "Free combination", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "BI 1356", 
                "Metformin"
            ]
        }, 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Petersburg", 
                    "country": "Russian Federation"
                }, 
                "name": "1288.21.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto\u00ae (Two Fixed Dose Combination Tablets of Linagliptin 2.5 mg and Metformin 500 mg) Compared With the Free Combination of Linagliptin 5 mg and Metformin 1000 mg Tablets Under Fasting Conditions.", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Pharmacological Committee, Ministry of Health"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Linagliptin: AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours)", 
                "safety_issue": "No", 
                "time_frame": "72hours"
            }, 
            {
                "measure": "Metformin: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }, 
            {
                "measure": "Linagliptin: Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }, 
            {
                "measure": "Metformin: Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947153"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Linagliptin and metformin: AUC 0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }, 
            {
                "measure": "Linagliptin: AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}